Evidence map›Paper›PMID 37046763›Full record

ArticleCancers2023

Phase IIa Clinical Biomarker Trial of Dietary Arginine Restriction and Aspirin in Colorectal Cancer Patients.

Jason A Zell, Thomas H Taylor, C Gregory Albers, Joseph C Carmichael, Christine E McLaren, Lari Wenzel, Michael J Stamos

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00578721 (Phase IIA Clinical Biomarker Trial of Aspirin and Arginine Restriction in Colorectal Cancer Patients), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00578721 phase2completednot on this map

Phase IIA Clinical Biomarker Trial of Aspirin and Arginine Restriction in Colorectal Cancer Patients

TypeinterventionalSponsorUniversity of California, IrvineRan2008 to 2013Enrolled24ConditionsColorectal CancerArmsAspirin
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jason A ZellDivision of Hematology/Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, CA 92868, USA.ORCID 0000-0003-2661-904X
Thomas H TaylorDepartment of Epidemiology & Biostatistics, University of California Irvine, Irvine, CA 92697, USA.
C Gregory AlbersDivision of Gastroenterology, Department of Medicine, University of California Irvine Medical Center, Orange, CA 92868, USA.ORCID 0000-0002-5972-7891
Joseph C CarmichaelDivision of Colorectal Surgery, Department of Surgery, University of California Irvine Medical Center, Orange, CA 92868, USA.ORCID 0000-0003-2738-7113
Christine E McLarenChao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA.
Lari WenzelChao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA.
Michael J StamosDivision of Colorectal Surgery, Department of Surgery, University of California Irvine Medical Center, Orange, CA 92868, USA.ORCID 0000-0003-2068-7391
University of California, Irvine Medical Center · USUniversity of California, Irvine · US

Funding

ZOVIRAX CREAM TO TREAT HERPES LABIALIS IN ADOLESCENTSM01RR000827 · NCRR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAAS, RICHARD H · 1985 to 2010
$74.3M
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Risk reduction through polyamine inhibition among colorectal carcinoma patientsK23CA133142 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZELL, JASON · 2009 to 2012
$711k
NCI NIH HHS K23 CA133142NCI NIH HHS P30 CA062203NCRR NIH HHS M01 RR000827NIH HHS K23 CA133142NIH HHS M01 RR00827NIH HHS P30 CA062203
6 · The paper itself

Abstract

After potentially curative treatment, colorectal cancer (CRC) patients remain at high risk for recurrence, second primary CRC, and high-risk adenomas. In combination with existing data, our previous findings provide a rationale for reducing tissue polyamines as tertiary prevention in non-metastatic CRC patients. The goal of this study was to demonstrate rectal tissue polyamine reduction in optimally treated stage I-III CRC patients after intervention with daily oral aspirin + dietary arginine restriction. A single-institution phase IIa clinical trial was conducted. Patients were treated with aspirin 325 mg/day and an individualized dietary regimen designed to reduce arginine intake by ≥30% over a 12-week study period. Dietary intake, endoscopy with rectal biopsies, and phlebotomy were performed pre- and post-intervention. The primary endpoint was to demonstrate ≥50% decrease in rectal tissue putrescine levels from baseline as a measure of polyamine reduction in the target tissue. Twenty eligible patients completed the study. After study intervention, mean dietary arginine intake decreased from 3.7 g/day ± 1.3 SD to 2.6 g/day ± 1.2 SD (29.7% decrease,

Indexed as

arginine restrictionaspirincancer preventionclinical trialcolorectal cancerdietary interventionpolyamines

Identifiers

PMID37046763
PMCPMC10093153
OpenAlexW4362467966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.